{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:29:34Z","timestamp":1784687374154,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2820-z","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T13:07:15Z","timestamp":1510837635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review"],"prefix":"10.1186","volume":"17","author":[{"given":"Hosnieh","family":"Fathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9579-4469","authenticated-orcid":false,"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"2820_CR1","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. Available from: http:\/\/www.easl.eu\/medias\/EASLimg\/News\/easl_recommendations_hcv_2014_full.pdf . Accessed Jan 2017."},{"key":"2820_CR2","unstructured":"National Institute for Health and Care Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance [TA75]. 2004. 22 August 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta75 . Accessed Jan 2017."},{"key":"2820_CR3","unstructured":"National Institute for Health and Care Excellence. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance [TA200]. 2010. 15 August 2014. Available from: https:\/\/www.nice.org.uk\/guidance\/TA200 . Accessed Jan 2017."},{"issue":"34","key":"2820_CR4","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"A Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti A. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824\u201340.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2820_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03763.x","volume":"28","author":"A Andriulli","year":"2008","unstructured":"Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28(4):397\u2013404.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2820_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","volume":"60","author":"F Kanwal","year":"2014","unstructured":"Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology. 2014;60(1):98\u2013105.","journal-title":"Hepatology"},{"issue":"9 Suppl 2","key":"2820_CR7","first-page":"3","volume":"74","author":"CJ Wu","year":"2015","unstructured":"Wu CJ, Roytman MM, Hong LK, Huddleston J, Trujillo R, Cheung A, et al. Real-world experience with sofosbuvir-based regimens for chronic hepatitis C, including patients with factors previously associated with inferior treatment response. Hawaii J Med Public Health. 2015;74(9 Suppl 2):3\u20137.","journal-title":"Hawaii J Med Public Health"},{"key":"2820_CR8","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394. http:\/\/doi.org\/10.1016\/j.jhep.2016.09.001 .","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"2820_CR9","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version April 2016. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/205035\/1\/9789241549615_eng.pdf?ua=1 . Accessed Jan 2017."},{"key":"2820_CR10","unstructured":"American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. Available from: http:\/\/www.hcvguidelines.org \/. Accessed Jan 2017."},{"key":"2820_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2015.03.014","volume":"479\u2013480","author":"MT Catanese","year":"2015","unstructured":"Catanese MT, Dorner M. Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology. 2015;479\u2013480:221\u201333.","journal-title":"Virology"},{"key":"2820_CR12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","volume":"39","author":"J Ampuero","year":"2014","unstructured":"Ampuero J, Romero-G\u00f3mez M, Reddy KR, et al. HCV genotype 3 \u2013 the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2820_CR13","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altmann G. The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"4","key":"2820_CR14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","volume":"21","author":"MF Freeman","year":"1950","unstructured":"Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Statist. 1950;21(4):607\u201311.","journal-title":"Ann Math Statist"},{"issue":"11","key":"2820_CR15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Rosana E, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974\u20138.","journal-title":"J Epidemiol Community Health"},{"key":"2820_CR16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"issue":"7414","key":"2820_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"2820_CR18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the \u2018binomial. Biometrika. 1934;26:404\u201313.","journal-title":"Biometrika"},{"issue":"2","key":"2820_CR19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.clinthera.2015.12.017","volume":"38","author":"E Swallow","year":"2016","unstructured":"Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, et al. Daclatasvir and sofosbuvir versus sofosbuvir and ribavirin in patients with chronic hepatitis C coinfected with HIV: a matching-adjusted indirect comparison. Clin Ther. 2016;38(2):404\u201312.","journal-title":"Clin Ther"},{"issue":"6","key":"2820_CR20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631\u201340.","journal-title":"JAMA"},{"key":"2820_CR21","unstructured":"Merck, 2017. Merck Discontinues MK-3682B and MK-3682C Development Programs. Available from: http:\/\/www.mrknewsroom.com\/news-release\/corporate-news\/merck-discontinues-mk-3682b-and-mk-3682c-development-programs . Accessed Oct 2017."},{"key":"2820_CR22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski M, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867\u201377.","journal-title":"N Engl J Med"},{"key":"2820_CR23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"EL Lawitz","year":"2013","unstructured":"Lawitz EL, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chonic hepatitis C infection. N Engl J Med. 2013;368:1878\u201387.","journal-title":"N Engl J Med"},{"issue":"3","key":"2820_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiv005","volume":"212","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367\u201377.","journal-title":"J Infect Dis"},{"issue":"27","key":"2820_CR25","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328.","journal-title":"N Engl J Med"},{"key":"2820_CR26","unstructured":"Foster GR, Thompson AJ, Ruane PJ, Borgia S, Dore G, Workowski K, et al. A randomized phase 3 trial of sofosbuvir\/velpatasvir\/voxilaprevir for 8 weeks and sofosbuvir\/velpatasvir for 12 weeks for patients with genotype 3 HCV infection and cirrhosis: The POLARIS-3 Study. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting 2016. Boston, November 11\u201315, 2016. Abstract 258."},{"key":"2820_CR27","doi-asserted-by":"crossref","unstructured":"Kwo PY, Wyles DL, Wang S, Poordad F, Gane E, Maliakkal B, et al. 100% SVR12 with ABT-493 and ABT-530 with or without ribavirin in treatment-na\u00efve HCV genotype 3-infected patients with cirrhosis. 51st Annual Meeting of the European Association for the Study of the Liver: Barcelona April 13\u201317, 2016. Abstract LB01.","DOI":"10.1016\/S0168-8278(16)00170-7"},{"key":"2820_CR28","unstructured":"Foster GR, Cooper C, Molina J-M, Naggie S, Huang KC, Osinusi A, et al. C-ISLE: Grazoprevir\/elbasvir plus sofosbuvir in treatment-na\u00efve and treatment-experienced HCV GT3 cirrhotic patients treated for 8, 12 or 16 weeks. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting 2016. Boston, November 11-15, 2016. Abstract 74."},{"key":"2820_CR29","unstructured":"Janssen, 2017. Janssen to Discontinue Hepatitis C Development Program. Available from: http:\/\/www.janssen.com\/janssen-discontinue-hepatitis-c-development-program . Accessed Oct 2017."},{"key":"2820_CR30","first-page":"585","volume":"2","author":"A Bruchfeld","year":"2017","unstructured":"Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londo\u00f1o MC, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. Gastroenterol Hepatol. 2017;2:585\u201394.","journal-title":"Gastroenterol Hepatol"},{"key":"2820_CR31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4254\/wjh.v9.i4.180","volume":"9","author":"E Cholongitas","year":"2017","unstructured":"Cholongitas E, Pipili C, Papatheodoridis GV. Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. World J Hepatol. 2017;9:180\u201390.","journal-title":"World J Hepatol"},{"key":"2820_CR32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109\u201317.","journal-title":"Ann Intern Med"},{"key":"2820_CR33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, L\u00ea MP, Gervais A, Heurgu\u00e9-Berlot A, Laradi A, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40\u20137.","journal-title":"J Hepatol"},{"key":"2820_CR34","doi-asserted-by":"publisher","unstructured":"Fabrizi F, Donato FM, and Messa P. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. Int J Artif Organs. 8 July 2017 [epub ahead of print]. doi: 10.5301\/ijao.5000613","DOI":"10.5301\/ijao.5000613"},{"key":"2820_CR35","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590\u20138.","journal-title":"Gastroenterology"},{"key":"2820_CR36","doi-asserted-by":"publisher","unstructured":"Reddy KR, Roth D, Bruchfeld A, Hwang P, Haber B, Robertson MN, et al. Elbasvir\/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 23 March 2017 [epub ahead of print]. doi: 10.1111\/hepr.12899 .","DOI":"10.1111\/hepr.12899"},{"key":"2820_CR37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537\u201345.","journal-title":"Lancet"},{"key":"2820_CR38","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","author":"V Saxena","year":"2017","unstructured":"Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology. 2017;66:1090\u2013101.","journal-title":"Hepatology"},{"key":"2820_CR39","unstructured":"AASLD and IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. Available at: http:\/\/hcvguidelines.org\/ . Accessed Oct 2017."},{"key":"2820_CR40","doi-asserted-by":"publisher","unstructured":"Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, et al. Grazoprevir, ruzasvir, and uprifosbuvir for HCV after NS5A treatment failure. Hepatology. 7 July 2017 [epub ahead of print]. doi: 10.1002\/hep.29358 .","DOI":"10.1002\/hep.29358"},{"key":"2820_CR41","doi-asserted-by":"publisher","unstructured":"Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir\/pibrentasvir for HCV genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase III clinical trial. Hepatology. 19 September 2017 [epub ahead of print]. doi: 10.1002\/hep.29541 .","DOI":"10.1002\/hep.29541"},{"key":"2820_CR42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2017.1351295","volume":"11","author":"R Voaklander","year":"2017","unstructured":"Voaklander R, Jacobson IM. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017;11:789\u201395.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2820_CR43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/acs.jmedchem.6b01310","volume":"60","author":"L Tong","year":"2017","unstructured":"Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, et al. Discovery of ruzasvir (mk-8408): a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms. J Med Chem. 2017;60:290\u2013306.","journal-title":"J Med Chem"},{"key":"2820_CR44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389\u201397.","journal-title":"Hepatology"},{"key":"2820_CR45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/1060028017704857","volume":"51","author":"S Molino","year":"2017","unstructured":"Molino S, Martin MT. Hepatitis c virus resistance testing in genotype 1: the changing role in clinical utility. Ann Pharmacother. 2017;51:811\u20136.","journal-title":"Ann Pharmacother"},{"key":"2820_CR46","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","volume":"65","author":"E Lawitz","year":"2017","unstructured":"Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803\u20139.","journal-title":"Hepatology"},{"key":"2820_CR47","doi-asserted-by":"publisher","unstructured":"Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 9 August 2017 [epub ahead of print]. doi: 10.1016\/S2468-1253(17)30163-2 .","DOI":"10.1016\/S2468-1253(17)30163-2"},{"issue":"4","key":"2820_CR48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","volume":"66","author":"EJ Gane","year":"2017","unstructured":"Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017;66(4):1083\u20139.","journal-title":"Hepatology"},{"key":"2820_CR49","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134\u201346.","journal-title":"N Engl J Med"},{"key":"2820_CR50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","volume":"151","author":"EJ Gane","year":"2016","unstructured":"Gane EJ, Schwabe C, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3\/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016;151:448\u201356.","journal-title":"Gastroenterology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T03:30:44Z","timestamp":1570332644000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2820-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2820-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"article-number":"722"}}